Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 403.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 247,030 shares of the biopharmaceutical company's stock after acquiring an additional 197,918 shares during the period. Two Sigma Investments LP owned approximately 0.19% of Halozyme Therapeutics worth $11,811,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HALO. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust raised its position in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

HALO traded up $0.35 during trading on Thursday, reaching $54.78. 364,587 shares of the company were exchanged, compared to its average volume of 1,620,672. The stock has a market cap of $6.75 billion, a P/E ratio of 15.97, a PEG ratio of 0.42 and a beta of 1.26. The firm has a 50 day moving average of $59.27 and a 200 day moving average of $55.74. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm's revenue was up 35.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.79 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. The trade was a 1.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 10,000 shares of company stock worth $597,151 in the last three months. 2.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HALO shares. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Thursday. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Finally, Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.